Rossari Biotech Q1 FY27: net profit up 4% to ₹35.1 crore, revenue up 28%
Rossari Biotech (ROSSARI) said it has published its Q1 FY27 results (consolidated), reporting revenue of ₹697 crore (+28.2% year on year), net profit of ₹35.1 crore (+4.5%), earnings per share of ₹6.34. The company is valued at about ₹2,518 crore.
What happened
Rossari Biotech (ROSSARI) told the exchanges on 17 October 2026 at 07:54 PM that it has published its Q1 FY27 results (consolidated), reporting revenue of ₹697 crore (+28.2% year on year), net profit of ₹35.1 crore (+4.5%), earnings per share of ₹6.34.
Company snapshot
Rossari Biotech is a small-cap company, with a market value of about ₹2,518 crore.
The stock last traded at ₹454.7, against a 52-week range of ₹375–₹688 (33.9% below the high).
Before this filing the shares had moved +3.9% over the month and −12.3% over three months. Average daily turnover over the last 20 sessions was about ₹3.06 crore.
Promoters held 68.14% at the end of Q1 FY27, down 0.01% points from the previous quarter. Foreign institutions owned 2.02% and domestic institutions 14.64%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 544 | 33.6 | 6.07 |
| Q2 FY26 | 1,130 | 70.5 | 12.76 |
| Q3 FY26 | 582 | 32.8 | 5.92 |
| Q4 FY26 | 685 | 46 | 8.3 |
| Q1 FY27 | 697 | 35.1 | 6.34 |
What history shows
This is not the company's first results disclosure: BCEIE has 2 earlier filings of this kind on record since May 2026.
After those filings, the stock fell 3.6% on average the next trading day and was down 2.2% on average after five days (2 filings with price data).
Market-wide, 9,607 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 19 Jul 2026 | Results | −3.6% | −2.2% |
| 18 Jul 2026 | Unaudited Financial Results (Standalone And Consolidated) For The… | −3.6% | −2.2% |
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 17 October 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.